Evidence map›Paper›PMID 40394591›Full record

ReviewJournal of nanobiotechnology2025

Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems.

Maoze Wang, Huina Liu, Jinling Huang, Ting Cai, Zhi Ping Xu, Lingxiao Zhang

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maoze Wang *Guoke Ningbo Life Science and Health Industry Research Institute, Ningbo, 315040, China.
Huina Liu *Guoke Ningbo Life Science and Health Industry Research Institute, Ningbo, 315040, China.
Jinling HuangInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518107, China.
Ting CaiGuoke Ningbo Life Science and Health Industry Research Institute, Ningbo, 315040, China. caiting@ucas.ac.cn.
Zhi Ping XuGuoke Ningbo Life Science and Health Industry Research Institute, Ningbo, 315040, China. gordonxu@szbl.ac.cn.
Lingxiao ZhangInterdisciplinary Nanoscience Center (INANO), Aarhus University, Aarhus C, DK-8000, Denmark. zhanglx@inano.au.dk.

Funding

H2020 Marie Skłodowska-Curie Actions 101064861Innovative Teams of Ningbo Yongjiang Talent Programme 2023A-365-CMedical Scientific Research Foundation of Zhejiang Province, China 2023KY1080National Natural Science Foundation of China 32101123Natural Science Foundation of Ningbo Municipality 2022J273Ningbo Health Science and Technology Project 2023Y36Young Talents of Ningbo Yongjiang Talent Programme 2021A-010-G
6 · The paper itself

Abstract

Gene therapy holds immense potential due to its ability to precisely target oncogenes, making it a promising strategy for cancer treatment. Advances in genetic science and bioinformatics have expanded the applications of gene delivery technologies beyond detection and diagnosis to potential therapeutic interventions. However, traditional gene therapy faces significant challenges, including limited therapeutic efficacy and the rapid degradation of genetic materials in vivo. To address these limitations, multifunctional nanoparticles have been engineered to encapsulate and protect genetic materials, enhancing their stability and therapeutic effectiveness. Nanoparticles are being extensively explored for their ability to deliver various genetic payloads-including plasmid DNA, messenger RNA, and small interfering RNA-directly to cancer cells. This review highlights key gene modulation strategies such as RNA interference, gene editing systems, and chimeric antigen receptor (CAR) technologies, alongside a diverse array of nanoscale delivery systems composed of polymers, lipids, and inorganic materials. These nanoparticle-based delivery platforms aim to improve targeted transport of genetic material into cancer cells, ultimately enhancing the efficacy of cancer therapies.

Indexed as

Genetic TherapyGene Transfer TechniquesNanoparticlesNeoplasmsAnimalsGene EditingHumansRNA InterferenceRNA, Small InterferingRNA, Small InterferingCancer gene therapyCAR technologiesGene editingNanoparticles

Identifiers

PMID40394591
PMCPMC12090605

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.